Glenn Foundation For Medical Research Welcomes Dr. Kevin Lee As Senior Advisor

SANTA BARBARA, Calif., Dec. 7, 2014 /PRNewswire-USNewswire/ -- The Glenn Foundation for Medical Research, whose mission is to extend the healthy, productive years of life through research on the biological mechanisms of aging, has today announced the appointment of Kevin J. Lee, Ph.D. as its Senior Scientific & Programmatic Advisor. Dr. Leehas most recently served as the Executive Director of the Ellison Medical Foundation. "We are pleased to add someone with such exceptional experience to the Glenn Foundation team," said Mark Collins, President of the Glenn Foundation. "Through his work with the Ellison Medical Foundation, Kevin has accumulated an extensive understanding of the aging research field. Although we have collaborated with Kevin in the past, being able to utilize Kevin's experience and vision on a day-to-day basis greatly strengthens our capabilities."  

Dr. Lee is a graduate of the University of Michigan and received his Ph.D. in biology from the Massachusetts Institute of Technology. His career spans over 25 years of research experience in molecular genetics and neurobiology in biotechnology, academic research and not-for-profit settings. He serves on the Board of Directors of the American Federation for Aging Research.

Dr. Lee was appointed Executive Director of the Ellison Medical Foundation in September 2012, having served as Deputy Executive Director from 2007-2012. Prior to joining the Ellison Medical Foundation, Dr. Lee served as Executive Vice President-Research of Sentigen Biosciences. He was responsible for the start-up and development of this New York City-based biotechnology company leading to its acquisition by Invitrogen Corporation in 2006. He has served as a member of the Scientific Review Board for the Simons Foundation Autism Research Initiative in New York. Dr. Lee's scientific research career employed genetic approaches to learn how neurons in the brain are "wired up" during development to make functional circuits that relay sensory information and control behavior. He worked with Dr. Thomas Jessell in the Center for Neurobiology and Behavior at Columbia University, where he studied the specification, axonal projection, and functional connectivity of nerve cells in the spinal cord. He is the recipient of biotechnology patents and is the author of numerous research publications.

About the Glenn Foundation for Medical Research. Inc.

Since its founding in 1965, the Glenn Foundation for Medical Research has supported basic research to better understand the biology that governs normal human aging and its related physiological decline, with the objective of developing interventions that will extend the healthy years of human life. In addition to its other programs the Glenn Foundation sponsors a consortium of "Glenn Center" laboratories at Harvard Medical School, Stanford School of Medicine, Massachusetts Institute of Technology, The Salk Institute, Albert Einstein School of Medicine, Princeton University, The Mayo Clinic, University of Michigan, University of California San Francisco and University California Berkeley.  For more information please visit

To view the original version on PR Newswire, visit:

SOURCE Glenn Foundation for Medical Research

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.